肿瘤生长和转移需要血管生成。纤溶酶原K5能够与血管内皮细胞特异性结合,并抑制血管内皮细胞增殖。此外,纤溶酶原K5分子量小。因此。通过放射性核素标记纤溶酶原K5,利用放射性核素的显像和治疗特性,结合纤溶酶原K5的血管抑制作用以及靶向肿瘤新生血管的特点,从而实现对肿瘤的显像和治疗。可见,对纤溶酶原K5进行放射性标记研究很有应用前景。 Tumor growth and metastasis require angiogenesis. Plasminogen K5 is able to specifically bind to vascular endothelial cells and inhibit the proliferation of vascular endothelial cells. In addition, plasminogen K5 has a small molecular weight. therefore. Through the radionuclide labeled plasminogen K5, the use of radionuclide imaging and therapeutic properties, combined with the inhibition of plasminogen K5 and tumor targeting neovasculature characteristics, so as to achieve the imaging of the tumor and treatment . Visible, radionuclide plasminogen K5 research is promising.